FindMyKOL
Clinical trialNCT03846583WithdrawnPhase 1Interventional

Tucatinib + Abemaciclib + Herceptin for HER2+ MBC

SponsorDana-Farber Cancer InstituteEnrollment0Breast Cancer
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This research study is studying a combination of drugs as a possible treatment for HER2-Postive Metastatic Breast Cancer. The interventions involved in this study are: * Tucatinib * Abemaciclib (VerzenioTM) * Trastuzumab (Herceptin®) * Endocrine Therapy: Exemestane (Aromasin®), Letrozole (Femara®), or Anastrozole (Arimidex®)
clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

No facility list is in our current data snapshot for this study. The registry record on ClinicalTrials.gov ↗ carries any published locations. Why? →

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Abemaciclib →Aromatase InhibitorTrastuzumab →Tucatinib →
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
28 Jun 2020
Primary completion
22 Sept 2020
Completion
22 Sept 2020
Last update posted
23 Oct 2020
Registered enrollment
0
Registry id
NCT03846583
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.